No Data
No Data
Express News | Iflyteck Says It Invests 100 Mln Yuan in AI Venture Capital Fund It Set up With Partners
Market Cap 10.5 billion Hong Kong dollars! Iflytek Co.,ltd. Medical enters the Hong Kong stock market, and Liu Qingfeng from Iflytek Co.,ltd. expands the capital territory with another success.
① Iflytek Co.,ltd. Medical is derived from Iflytek Co.,ltd. Focusing on the field of AI, Liu Qingfeng's Iflytek Co.,ltd. has made arrangements in multiple areas, including Education, Medical, Siasun Robot&Automation, and other fields. ② However, the AI Medical Business involves patient information, and the 'Iflytek Xiaoyi' application developed by Iflytek Medical has issues with collecting personal information beyond the scope, as reported by the Ministry of Industry and Information Technology.
China Galaxy Securities: The era of AI agents is flourishing, and the Technology domestic demand is welcoming a new chapter.
The alleviation of local government debt risks helps provide ample funding support for digital infrastructure and other infrastructures, which is expected to increase Industry informatization Orders and drive marginal improvement in Industry Cash / Money Market flow.
Open-source Securities: The turning point for AI agents has arrived, with both B2B and B2C flourishing.
AI agent applications will flourish in multiple areas in 2025.
Is IFLYTEKLTD (SZSE:002230) A Risky Investment?
Iflytek Co.,ltd. (002230.SZ): The controlling subsidiary Iflytek Medical has published the prospectus for Listed in Hong Kong, the issuance price for Listed in Hong Kong, and matters related to the public offering in Hong Kong.
On December 18, Glonghui reported that Iflytek Co.,ltd. (002230.SZ) announced that on December 18, 2024, its holding subsidiary Iflytek Medical will publish and distribute the H share prospectus for this issuance and listing on the Hong Kong Stock Exchange website in accordance with relevant regulations. This H share prospectus is published in accordance with applicable Hong Kong laws and regulations, as well as the relevant rules and requirements of the Hong Kong Stock Exchange and the Hong Kong Securities and Futures Commission. Some of the contents included may differ from the relevant documents prepared or published by Iflytek Medical in accordance with Chinese laws and regulations, including but not limited to those included in the prospectus based on international laws.